Expression of Asialoglycoprotein Receptor in Human Fetal Liver.

Yoshida, Seiya; Furuhashi, Madoka; Suganuma, Nobuhiko

doi:10.1507/endocrj.46.67

Cited by 6 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are consistent with available data on placental transfer indicating limited transfer for large negatively charged molecules without active transport (48). Moreover, the GalNAc 3 -conjugated siRNA requires receptor-mediated uptake by the asialoglycoprotein receptor, which is not expressed appreciably in fetal liver until near delivery (49,50). Thus, the use of a maternal livertargeted isoform-specific siRNA in a transgenic model allows the reduced FGR).…”

Section: Discussionsupporting

confidence: 87%

RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models

Haase¹,

Foster²,

Cunningham³

et al. 2020

Journal of Clinical Investigation

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 87%

RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models

Haase¹,

Foster²,

Cunningham³

et al. 2020

Journal of Clinical Investigation

View full text Add to dashboard Cite

“…on May 12, 2018. by guest www.bloodjournal.org From other than hAFP or hAlb: CK18, a marker for hepatocytes; AGPR, of which distribution is mainly found on hepatocytes; 34 and CK19, a marker for hepatic progenitor or cholangiocytes (Figure 4). At day 14, all 3 markers were stained diffusely in cytoplasm; at day 28, CK19 was barely detectable, but the intensity for CK18 and AGPR rather increased.…”

Section: Human Mscs Give Rise To Liver With No Fusion In Rat 759mentioning

confidence: 99%

Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion

Sato

Araki

Kato

et al. 2005

Blood

555

344

View full text Add to dashboard Cite

Hepatic transdifferentiation of bone marrow cells has been previously demonstrated by intravenous administration of donor cells, which may recirculate to the liver after undergoing proliferation and differentiation in the recipient's bone marrow. In the present study, to elucidate which cellular components of human bone marrow more potently differentiate into hepatocytes, we fractionated human bone marrow cells into mesenchymal stem cells (MSCs) Schwartz et al 1 demonstrated that multipotent adult progenitor cells (MAPCs) 2,3 from the bone marrow of humans as well as mice and rats, when cultured with fibroblast growth factor-4 (FGF-4) and hepatocyte growth factor (HGF) in matrigel, secreted albumin, expressed P450, took up low-density lipoprotein (LDL), and stored glycogen. 3 Lee et al reported that mesenchymal stem cells (MSCs) from human bone marrow and umbilical cord blood differentiated into hepatocyte-like cells with the use of HGF and oncostatin M. 4,5 Most recently, Jang et al reported that hematopoietic stem cells (HSCs) from mice devoid of progenitors and selected for unique properties displayed a plasticity by which they became liver cells when cocultured with injured liver separated by a barrier. 6 Thus, the origin of cells which may undergo hepatic differentiation as revealed by in vitro experiments were quite diverse, reflecting the sources, human or rodent, and methods of isolation.,The differentiation of bone marrow or umbilical cord blood derived cells into hepatocytes has also been demonstrated by in vivo transplantation procedures. In most of these transplantation studies, either isolated 7-12 or clonally defined [13][14][15][16][17][18][19][20][21] HSCs of donor origin, though their characteristics were not equally specified in each study, were found to induce hepatocytes in recipient liver, suggesting the differentiation potency of HSCs.However, in these studies HSCs were generally introduced intravenously and were surmised to reside once in bone marrow where they may undergo proliferation and differentiation. Therefore, the cells distributed to the liver via bone marrow may not necessarily represent the original HSCs themselves.In fact, some recent studies have disclosed that hepatocytes with apparent donor characters were the result of fusion of donor myelomonocytic cells differentiated from HSCs with host hepatocytes. 20,22 Further, the results of these studies with HSCs do not exclude the possibility that other cell types in bone marrow such as MSCs are also capable of undergoing hepatic differentiation. Thus, issues still remained to be clarified as to which cellular component of bone marrow is most suitable to bring about hepatic regeneration in consideration of future clinical application. It also remains to be solved if any bone marrow components indeed differentiate in vivo without fusion.In the present investigation, we attempted to examine the differentiation ability of fractionated human bone marrow components-MSCs, CD34 ϩ cells, and non-MSCs/CD34 Ϫ cells-into hepatocytes in vivo ...

show abstract

“…The developed and validated PBPK model in pregnant women can be further developed by incorporating a fetal compartment to a maternal-fetal PBPK (mf-PBPK) model to predict placental and fetal transfer of siRNA. For example, ASGPR has been shown to be expressed in the human placenta (Vyas et al, 2018) and detected in fetal liver tissue (Yoshida et al, 1999). This expression pattern can be incorporated into the mf-PBPK model to predict transplacental transfer and fetal exposure of GalNAc-siRNA to assess fetal risk from maternal siRNA exposure.…”

Section: Pbpk Modeling To Predict Sirna Disposition During Pregnancymentioning

confidence: 99%

The ADME characteristics of siRNA therapeutics and the opportunity to predict disposition in pregnant women.

Amaeze,

Isoherranen,

Shum

2024

Drug Metab Dispos

View full text Add to dashboard Cite

Expression of Asialoglycoprotein Receptor in Human Fetal Liver.

Cited by 6 publications

References 33 publications

RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models

RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models

Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion

The ADME characteristics of siRNA therapeutics and the opportunity to predict disposition in pregnant women.

Contact Info

Product

Resources

About